At the news
? BEARISHIMPACT 7/10 8-K filed Feb 26, 2026 at 08:32 ET
Disc Medicine reported a significant increase in net loss to $212.2 million in 2025, primarily due to higher R&D and SG&A expenses. Despite receiving a Complete Response Letter (CRL) from the FDA for bitopertin, the company maintains a strong cash position of $791.2 million, providing runway into 2029. The company is advancing its pipeline with positive data from DISC-0974 in myelofibrosis and progressing other clinical trials.
- Net loss increased to $212.2 million in 2025 from $109.4 million in 2024
- Received Complete Response Letter (CRL) from FDA for bitopertin in EPP
- Cash position is $791.2 million, providing runway into 2029
- R&D expenses increased to $170.6 million from $96.7 million
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access